dabigatran and verapamil

Verapamil is a P-glycoprotein (P-gp) inhibitor. Dabigatran etexilate is a P-gp substrate; its intestinal absorption and renal clearance depend on P-gp. Verapamil co-administration reduces dabigatran efflux, increasing dabigatran plasma concentrations. From a pharmacodynamic perspective, enhanced dabigatran exposure directly increases anticoagulant activity, raising bleeding risk. The effect is formulation-dependent, with a greater interaction observed with the immediate-release form.

Elevated dabigatran levels can lead to excessive anticoagulation, increasing the risk of major bleeding events, including gastrointestinal and intracranial haemorrhage. The clinical impact varies, but the combination has been associated with higher bleeding risk, particularly in older patients and those with renal impairment. The magnitude of increase depends on dose, formulation and renal function.

Avoid the combination unless clearly necessary. If co-prescribed, reduce dabigatran dose to the lower approved regimen (e.g., 110 mg twice daily) when indicated, and monitor closely for bleeding signs and symptoms. Check renal function before and during therapy. Consider an alternative anticoagulant with a more predictable profile, e.g., apixaban or edoxaban, or an alternative antiarrhythmic agent.

Supported by pharmacokinetic studies reporting increased dabigatran exposure with verapamil. Clinical guidance from regulatory bodies and expert consensus advises caution or avoidance. Effect is well-documented in prescribing information, though head-to-head clinical outcome trials are limited.